ConductScience.org, home
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
API referenceFor AI assistants

Trial · NCT03371017

Results by group58

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 58

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Overall Survival (OS) in PD-L1-positive PopulationPlacebo + Chemotherapy11.2495% Confidence Interval 9.00 to 13.31months
Overall Survival (OS) in PD-L1-positive PopulationAtezolizumab + Chemotherapy12.0995% Confidence Interval 10.12 to 15.08months
OS in Modified Intent-to-treat (mITT) PopulationPlacebo + Chemotherapy9.7995% Confidence Interval 8.44 to 11.96months
OS in Modified Intent-to-treat (mITT) PopulationAtezolizumab + Chemotherapy10.3595% Confidence Interval 8.90 to 12.88months
12-month Survival Rate in PD-L1-positive PopulationPlacebo + Chemotherapy47.5895% Confidence Interval 39.92 to 55.23percentage of participants
12-month Survival Rate in PD-L1-positive PopulationAtezolizumab + Chemotherapy50.2695% Confidence Interval 42.61 to 57.91percentage of participants
12-month Survival Rate in mITT PopulationPlacebo + Chemotherapy42.4495% Confidence Interval 35.23 to 49.66percentage of participants
12-month Survival Rate in mITT PopulationAtezolizumab + Chemotherapy46.2095% Confidence Interval 38.84 to 53.56percentage of participants
18-month Survival Rate in PD-L1-positive PopulationPlacebo + Chemotherapy32.4895% Confidence Interval 25.07 to 39.89percentage of participants
18-month Survival Rate in PD-L1-positive PopulationAtezolizumab + Chemotherapy33.6395% Confidence Interval 26.05 to 41.21percentage of participants
18-month Survival Rate in mITT PopulationPlacebo + Chemotherapy25.6895% Confidence Interval 19.15 to 32.21percentage of participants
18-month Survival Rate in mITT PopulationAtezolizumab + Chemotherapy27.0595% Confidence Interval 20.39 to 33.71percentage of participants
Progression-free Survival (PFS) in PD-L1-positive PopulationPlacebo + Chemotherapy3.5895% Confidence Interval 3.35 to 4.17months
Progression-free Survival (PFS) in PD-L1-positive PopulationAtezolizumab + Chemotherapy4.2195% Confidence Interval 3.71 to 5.62months
PFS in mITT PopulationPlacebo + Chemotherapy3.5895% Confidence Interval 3.06 to 3.81months
PFS in mITT PopulationAtezolizumab + Chemotherapy3.7195% Confidence Interval 2.83 to 4.01months
Objective Response Rate (ORR) in Response-evaluable Population, Subset of PD-L1-positive PopulationPlacebo + Chemotherapy28.395% Confidence Interval 21.45 to 35.98percentage of participants
Objective Response Rate (ORR) in Response-evaluable Population, Subset of PD-L1-positive PopulationAtezolizumab + Chemotherapy39.695% Confidence Interval 31.83 to 47.80percentage of participants
ORR in Response-evaluable Population, Subset of mITT PopulationPlacebo + Chemotherapy32.195% Confidence Interval 25.16 to 39.77percentage of participants
ORR in Response-evaluable Population, Subset of mITT PopulationAtezolizumab + Chemotherapy31.095% Confidence Interval 24.16 to 38.51percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03371017/results

API referenceFor AI assistants